ReviewCurrent opinion in pharmacology2020
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease.
Review in Current opinion in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Machine learning prediction models for intravenous immunoglobulin resistance in Kawasaki disease: a meta-analysis.BMC medical informatics and decision making · 2026Pooled it
- Intravenous immunoglobulin for the treatment of Kawasaki disease.The Cochrane database of systematic reviews · 2023Pooled it
- Expression of key genes in IVIG-unresponsive Kawasaki disease and their immune correlation based on bioinformatics analysis.Immunologic research · 2026Article
- A nomogram based on serum CHI3L1 for predicting IVIG nonresponse in children with Kawasaki disease.European journal of pediatrics · 2026Article
- Integrative machine learning identifies robust inflammation-related diagnostic biomarkers and stratifies immune-heterogeneous subtypes in Kawasaki disease.Pediatric rheumatology online journal · 2025Article
- Ferroptosis-related oxidative stress activation in the acute phase of Kawasaki disease.Frontiers in immunology · 2025Article
- LncRNAs in Kawasaki disease and Henoch-Schönlein purpura: mechanisms and clinical applications.Molecular and cellular biochemistry · 2024Review
- Knowledge framework of intravenous immunoglobulin resistance in the field of Kawasaki disease: A bibliometric analysis (1997-2023).Immunity, inflammation and disease · 2024Article
- Susceptibility ofHeliyon · 2024Article
- Role of Pyroptosis in IVIG-Resistant Kawasaki Disease and the Establishment of a New Predictive Model.Journal of inflammation research · 2024Article
- Utilizing T-Lymphocyte Activation-Related Cytokines to Predict Non-Responsiveness to Treatment in Pediatric Kawasaki Disease.Pediatric health, medicine and therapeutics · 2024Article
- Restraint Stress-Induced Immunosuppression Is Associated with Concurrent Macrophage Pyroptosis Cell Death in Mice.International journal of molecular sciences · 2023Article
- Autoimmune Heart Disease: A Comprehensive Summary for Forensic Practice.Medicina (Kaunas, Lithuania) · 2023Review
- PTX3 promotes IVIG resistance-induced endothelial injury in Kawasaki disease by regulating the NF-κB pathway.Open life sciences · 2023Article
- Ultrasound evaluation of endothelial dysfunction in immunoglobulin-resistant children with acute Kawasaki disease.Clinical rheumatology · 2022Article
- Characterization of Inflammatory Factors and T Cell Subpopulations in a Murine Model of Kawasaki Disease Induced by Candida albicans Cell Wall Extracts (CAWS).Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Lymph-node-first presentation of Kawasaki disease in a 12-year-old girl with cervical lymphadenitis caused byWorld journal of clinical cases · 2022Article
- The Associated of the Risk of IVIG Resistance in Kawasaki Disease withJournal of inflammation research · 2022Article
- Association betweenFrontiers in cardiovascular medicine · 2022Article
- Kawasaki Disease- Management Strategies Given Symptoms Overlap to COVID-19: A Review.JNMA; journal of the Nepal Medical Association · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease is an acute childhood self-limited vasculitis, causing the swelling or inflammation of medium-sized arteries, eventually leading to cardiovascular problems such as coronary artery aneurysms. Acetylsalicylic acid combined with intravenous immunoglobulin (IVIG) is the standard treatment of Kawasaki disease (KD). However, a rising number of IVIG resistant cases were reported with severe disease complications such as the KD Shock Syndrome or KD-Macrophage activation syndrome. Recent reports have depicted the overlapped number of children with SARS-CoV-2 and KD, which was called multisystem inflammatory syndrome. Simultaneously, the incidence rate of KD-like diseases are increased after the outbreak of COVID-19, suggesting the virus may be associated with KD. New intervention is important to overcome the problem of IVIG treatment resistance. This review aims to introduce the current pharmacological intervention and possible resistance genes for the discovery of new drug for IVIG resistant KD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.